IDEXX Laboratories Beheer
Beheer criteriumcontroles 4/4
De CEO IDEXX Laboratories is Jay Mazelsky, benoemd in Jun2019, heeft een ambtstermijn van 5.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.52M, bestaande uit 8.7% salaris en 91.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.1% van de aandelen van het bedrijf, ter waarde $ 35.39M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.4 jaar en 8.1 jaar.
Belangrijke informatie
Jay Mazelsky
Algemeen directeur
US$11.5m
Totale compensatie
| Percentage CEO-salaris | 8.7% |
| Dienstverband CEO | 5.4yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 5.4yrs |
| Gemiddelde ambtstermijn bestuur | 8.1yrs |
Recente managementupdates
Recent updates
Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28
Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$866m |
| Jun 30 2024 | n/a | n/a | US$846m |
| Mar 31 2024 | n/a | n/a | US$867m |
| Dec 31 2023 | US$12m | US$1m | US$845m |
| Sep 30 2023 | n/a | n/a | US$823m |
| Jun 30 2023 | n/a | n/a | US$791m |
| Mar 31 2023 | n/a | n/a | US$699m |
| Dec 31 2022 | US$10m | US$1m | US$679m |
| Sep 30 2022 | n/a | n/a | US$670m |
| Jun 30 2022 | n/a | n/a | US$664m |
| Mar 31 2022 | n/a | n/a | US$735m |
| Dec 31 2021 | US$9m | US$977k | US$745m |
| Sep 30 2021 | n/a | n/a | US$757m |
| Jun 30 2021 | n/a | n/a | US$728m |
| Mar 31 2021 | n/a | n/a | US$674m |
| Dec 31 2020 | US$7m | US$814k | US$582m |
| Sep 30 2020 | n/a | n/a | US$497m |
| Jun 30 2020 | n/a | n/a | US$460m |
| Mar 31 2020 | n/a | n/a | US$437m |
| Dec 31 2019 | US$7m | US$632k | US$428m |
| Sep 30 2019 | n/a | n/a | US$423m |
| Jun 30 2019 | n/a | n/a | US$407m |
| Mar 31 2019 | n/a | n/a | US$390m |
| Dec 31 2018 | US$3m | US$555k | US$377m |
| Sep 30 2018 | n/a | n/a | US$330m |
| Jun 30 2018 | n/a | n/a | US$307m |
| Mar 31 2018 | n/a | n/a | US$284m |
| Dec 31 2017 | US$2m | US$469k | US$263m |
Compensatie versus markt: De totale vergoeding ($USD 11.52M ) Jay } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Jay is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jay Mazelsky (63 yo)
5.4yrs
Tenure
US$11,519,309
Compensatie
Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.4yrs | US$11.52m | 0.10% $ 35.4m | |
| CFO, Executive VP & Treasurer | 10.8yrs | US$3.85m | 0.060% $ 21.2m | |
| Executive VP and GM of Reference Laboratories & Information Technology | 4.8yrs | US$2.92m | 0.0086% $ 3.0m | |
| Senior Vice President of Global Operations | 7.2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Commercial Finance & Sales Operations | 9.8yrs | geen gegevens | geen gegevens | |
| Executive VP & CTO | 3.3yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Information Officer | 8.8yrs | geen gegevens | geen gegevens | |
| Executive VP | no data | US$1.88m | 0.0068% $ 2.4m | |
| Executive VP & Chief Human Resources Officer | 2.7yrs | geen gegevens | 0.00022% $ 78.0k | |
| Senior VP & Chief Revenue Officer | no data | geen gegevens | 0.0084% $ 3.0m | |
| Executive VP and GM of Point of Care Diagnostics & Telemedicine | no data | geen gegevens | 0.013% $ 4.6m | |
| Senior Vice President of Research & Development | 4.8yrs | geen gegevens | geen gegevens |
5.4yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IDXX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.1yrs | US$11.52m | 0.10% $ 35.4m | |
| Independent Director | 12.3yrs | US$367.66k | 0.0074% $ 2.6m | |
| Independent Director | 10.7yrs | US$362.66k | 0.0031% $ 1.1m | |
| Independent Director | 9.3yrs | US$367.66k | 0.0021% $ 744.6k | |
| Non-Employee Director | 22.8yrs | US$335.16k | 0.71% $ 250.2m | |
| Independent Director | 7.3yrs | US$350.16k | 0.0024% $ 854.5k | |
| Independent Non-Executive Chairman | 8.1yrs | US$495.02k | 0.0096% $ 3.4m | |
| Independent Director | 11.3yrs | US$335.16k | 0.011% $ 3.9m | |
| Independent Director | 1.3yrs | US$258.89k | 0.00025% $ 88.6k | |
| Independent Director | 5.3yrs | US$342.66k | 0% $ 0 | |
| Independent Director | 4yrs | US$335.16k | 0.00095% $ 336.8k |
8.1yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IDXX wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).